Wenying Shan

Taipa, Macao Special Administrative Region

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Benserazide‑mediated targeting hexokinase 2 enhances the cytotoxicity of cisplatin in non-small cell lung cancer cell models.

Benserazide‑mediated targeting hexokinase 2 enhances the cytotoxicity of cisplatin in non-small cell lung cancer cell models.

Journal: Biochemical pharmacology

Published: February 11, 2025

Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutation.

Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutation.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: November 02, 2024

Targeting hexokinase 2 to enhance anticancer efficacy of trichosanthin in HeLa and SCC25 cell models.

Targeting hexokinase 2 to enhance anticancer efficacy of trichosanthin in HeLa and SCC25 cell models.

Journal: ADMET & DMPK

Published: July 15, 2024

NF-κB activation as a pro-survival signal from pharmacological inhibition of pyruvate dehydrogenase kinase 1 in non-small-cell lung carcinoma cell models.

NF-κB activation as a pro-survival signal from pharmacological inhibition of pyruvate dehydrogenase kinase 1 in non-small-cell lung carcinoma cell models.

Journal: Translational oncology

Published: March 06, 2024

GcForest-based compound-protein interaction prediction model and its application in discovering small-molecule drugs targeting CD47.

GcForest-based compound-protein interaction prediction model and its application in discovering small-molecule drugs targeting CD47.

Journal: Frontiers in chemistry

Published: September 12, 2023

Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.

Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.

Journal: Cancer letters

Published: July 04, 2023

Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis.

Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis.

Journal: Phytotherapy research : PTR

Published: April 25, 2023

Repurposing the Hedgehog pathway inhibitor, BMS-833923, as a phosphatidylglycerol-selective membrane-disruptive colistin adjuvant against ESKAPE pathogens.

Repurposing the Hedgehog pathway inhibitor, BMS-833923, as a phosphatidylglycerol-selective membrane-disruptive colistin adjuvant against ESKAPE pathogens.

Journal: International journal of antimicrobial agents

Published: March 18, 2023

Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models.

Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models.

Journal: Chemico-biological interactions

Published: December 24, 2022

The development of small-molecule inhibitors targeting hexokinase 2.

The development of small-molecule inhibitors targeting hexokinase 2.

Journal: Drug discovery today

Published: January 29, 2022

Convolutional Neural Network-based Virtual Screening.

Convolutional Neural Network-based Virtual Screening.

Journal: Current medicinal chemistry

Published: February 11, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026